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INTRODUCTION      
   
 
         Mycobacterium tuberculosis is the bacteria that cause tuberculosis (TB). It has been present 
in the human population since antiquity - fragments of the spinal column from Egyptian 
mummies from 2400 BC show definite signs of tuberculosis. In 1882, Robert Koch discovered a 
staining technique that enabled him to see Mycobacterium tuberculosis. Tuberculosis is 
contagious and airborne. It ranks as the second leading cause of death from a single infectious 
agent, after the human immunodeficiency virus (HIV).
1
 
 
 
 
Fig.1: Electron microscope photograph of Mycobacterium tuberculosis. 
 
        Tubercle bacilli are the rod-shaped, which are spread mostly through air-born droplets or 
dust micro-particles of dried sputum. Once inhaled, the immune system reacts by engulfing the 
bacteria, forming a tubercle which prevents it from spreading.  
     
         In most cases, the bacteria will die. If it survives, it becomes dormant and the infected 
individual may develop active disease at a later date, sometimes soon after infection, sometimes 
years later. 
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           Those who develop active pulmonary tuberculosis experience a range of signs and 
symptoms, including chest pain, cough, weight loss, pallor, fever, and night sweats. People with 
suppressed immune systems, such as persons with HIV and AIDS, are prone to develop active 
tuberculosis. Only those with active TB are able to spread it, by coughing or sneezing. These 
actions release the bacteria from the lungs into the air, from where it can be inhaled by others. 
The bacteria are able to survive in the air for several hours, but are weakened by direct sunlight.
2
 
   
PATHOPHYSIOLOGY
 
         
        Humans are the only known reservoir for Mycobacterium tuberculosis. TB is transmitted by 
airborne droplet nuclei, which may contain fewer than 10 bacilli. TB exposure occurs by sharing 
common airspace with an individual who is in the infectious stage of TB. 
 
 
 
Fig.2: Pathogenesis of Mycobacterium tuberculosis. 
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1. Inhalation
 
        The bacteria are inhaled. The majority of the bacteria will become lodged in the upper 
respiratory tract, namely the nose and throat, where their survival is difficult. Some of the 
smaller particles, though, will make it into the lungs and alveoli where infection sets in. 
Alternatively, the bacteria might be ingested.
3 
 
2. Bacteria multiplication 
       In the alveoli, the bacteria are engulfed by inactivated macrophages, white blood cells 
present within tissues, where they multiply until the macrophage bursts. The Mycobacterium 
tuberculosis replicates very slowly, only once every twenty four hours, and takes up to one 
month to form a colony. 
 
3. T-cell activation 
       Dendritic cells are a key part of the mammalian immune system. When dendritic cells detect 
foreign substances entering the body, they engulf and bring them to the lymph nodes where they 
present the antigens to certain white blood cells called T-cells. If the T cell has a specific 
receptor for the presented antigen it will become activated to release potent molecules, such as 
interferon-gamma and tumour necrosis factor, which in turn stimulate macrophages and other T 
cells to produce a cell-mediated response against the bacteria carrying those antigens. 
 
4. Tubercle Formation
 
       The T-cells return to the site of infection through the blood stream, where they contribute to 
the formation of a tubercle or granuloma. The TB tubercle is made up of a core of infected 
macrophages, a surrounding ring of foamy macrophages and an outside ring of T-cells, all 
enveloped in a fibrous shell. In some cases, an individual's immune system is unable to defend 
against the bacteria by creating a tubercle to isolate it. Primary progressive tuberculosis occurs as 
a result. This is mostly seen in young children or individuals with much suppressed immune 
systems. 
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       When contained inside the granuloma the bacteria are inactive and the case of tuberculosis is 
considered to be latent. The bacteria are contained in the granuloma until the immune system is 
weakened, breaking down the outer ring of the tubercle, releasing the bacteria inside. In this 
situation, the case of tuberculosis has been reactivated and is known as secondary progressive 
tuberculosis. Only approximately 3-5% of immuno-competent individuals will develop 
secondary progressive tuberculosis within two years of the primary infection, and a further 3-5% 
will develop it after two years.
4 
 
5. Cavitation and Tubercle break-down
 
       In some cases, the damaged cells at the centre of the granuloma liquefy. The bacteria grow 
well in this liquid, multiplying outside of macrophages, their typical hosts. As they multiply, the 
tubercle enlarges. This can cause nearby tissue in the lungs to die and rupture, forming a cavity, 
or the tubercle to burst spreading bacteria further around the lungs or the body. This would also 
be considered a case of secondary progressive tuberculosis. The immune system will respond as 
per steps 3 & 4 when the bacteria are recognized in their new locations. 
 
      A small number of tubercle bacilli enter the bloodstream and spread throughout the body. 
The tubercle bacilli may reach any part of the body, including areas where TB disease is more 
likely to develop (such as the brain, larynx, lymph node, lung, spine, bone, or kidney).
5 
EPIDEMIOLOGY
 
         The highest incidences are seen in those countries of Africa, Asia, and Latin America. The 
World Health Organization estimates that nine million people get TB every year, of whom 95% 
live in developing countries. An estimated 2-3 million people die from TB every year.  
        8.6 million People fell ill with TB in 2012, including 1.1 million cases among people living 
with HIV. In 2012, 1.3 million people died from TB, including 320 000 among people who were 
HIV-positive. The TB mortality rate has decreased 45% since 1990, and the 2015 global target of 
a 50% reduction in mortality is now within reach.
6
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RISK FACTORS
 
 Working in the health care profession or as an embalmer  
 Being born in or spending time in a country where TB is common (for instance, most 
countries in Latin America and the Caribbean, Africa, and Asia, excluding Japan)  
 Living in overcrowded areas 
 Unsanitary settings where TB is common (for example, homeless shelters, migrant farm 
camps, prisons and jails, and some nursing homes or long-term care facilities)  
 Having HIV or AIDS. As HIV attacks the immune system, existing TB infections may 
become active, or it may make it easier for someone to catch TB. The TB bacteria, in 
turn, cause the HIV virus to replicate more quickly.  
 Using medications that suppress the immune system  
 Smoking and alcoholism 
 Organ transplantation  
 Having no or inadequate access to health care Having diabetes (the risk of contracting 
TB is 2-3 times higher among people who have diabetes compared to people who don't 
have diabetes)  
 Having a rheumatic disease 
 
TUBERCULOSIS SIGNS AND SYMPTOMS
 
 
 Mild fever  
 Headache  
 Chills, Night sweats  
 Fatigue  
 Loss of appetite,  weight loss 
 Cough with or without mucus and pus  
 Coughing up blood  
 Chest pain from inflammation in the lungs  
 Difficulty breathing  
 Sore throat.7 
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MEDICAL CARE
 
        The tuberculosis vaccine, known as bacille Calmette-Guerin (BCG) may prevent the spread 
of tuberculosis and tuberculous meningitis in children, but the vaccine does not necessarily 
protect against pulmonary tuberculosis. 
 
        The chemotherapy of infectious diseases, using sulfonamide and penicillins, had been 
underway for several years, but these molecules were ineffective against Mycobacterium 
tuberculosis. From 1943 Streptomycin was used in treatment. Following streptomycin, p-
aminosalicylic acid (1949), isoniazid (1952), pyrazinamide (1954), cycloserine (1955), 
ethambutol (1962), and rifampin (rifampicin; 1963) were introduced as anti-TB agents.The 
initial combination of isoniazid, rifampin, pyrazinamide, and ethambutal provide effective TB 
treatment.
8
 
DIRECTLY OBSERVED THERAPY             
       For initial empiric treatment of tuberculosis (TB), start patients on a 4-drug regimen: 
isoniazid, rifampin, pyrazinamide, and either ethambutol or streptomycin. Once the TB isolate is 
known to be fully susceptible, ethambutol (or streptomycin if used as a fourth drug) can be 
discontinued. 
       After 2 months of therapy (for a fully susceptible isolate), pyrazinamide can be stopped. 
Isoniazid plus rifampin are continued as daily or intermittent therapy for 4 more months. If 
isolated isoniazid resistance is documented, discontinue isoniazid and continue treatment with 
rifampin, pyrazinamide, and ethambutol for the entire 6 months. Therapy must be extended if the 
patient has cavitary disease or remains culture-positive after 2 months of treatment.
9
 
       Directly observed therapy (DOT) is recommended for all patients. Patients on the above 
regimens as DOT can be switched to 2- to 3-times per week dosing after an initial 2 weeks of 
daily dosing. Patients on twice-weekly dosing must not miss any doses. Prescribe daily therapy 
for patients on self-administered medication.
10
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DRUG RESISTANCE
 
       TB organisms resistant to the antibiotics used in its treatment are widespread and occur in all 
countries. Drug resistance emerges as a result of inadequate treatment and once TB organisms 
acquire resistance they can spread from person to person in the same way as drug-sensitive TB. 
 
MDR-TB
 
       
       Multidrug-resistant TB (MDR-TB) is caused by organisms that are resistant to the most 
effective anti-TB drugs (isoniazid and rifampicin). MDR-TB results from either infection with 
organisms which are already drug-resistant or may develop in the course of a patient's 
treatment.
11 
 
XDR-TB
 
 
       Extensively drug-resistant TB (XDR-TB) is a form of TB caused by organisms that are 
resistant to isoniazid and rifampicin (i.e. MDR-TB) as well as any fluoroquinolone and any of 
the second–line anti-TB injectable drugs (amikacin, kanamycin or capreomycin). 
     
         These forms of TB do not respond to the standard six month treatment with first-line anti-
TB drugs and can take two years or more to treat with drugs that are less potent, more toxic and 
much more expensive.
12 
 
THE NEED FOR NEW TUBERCULOSIS DRUGS
 
 
       There are reasons usually given for the need of new tuberculosis drugs: 
 To shorten the total duration of treatment. 
 To prevent complications and development of latency 
 To prevent subsequent recurrences 
 To improve the treatment of MDR- TB 
 To provide more effective treatment for latent tuberculosis infection (LTBI) 
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 To reduce both the total length of treatment and the frequency of drug 
administration. 
 CELL WALL OF MYCOBACTERIUM TUBERCULOSIS
 
         Mycobacterium tuberculosis has a unique cell wall structure crucial for its survival. The 
well- developed cell wall contains a considerable amount of a fatty acid, mycolic acid, 
covalently attached to the underlying peptidoglycan bound polysaccharide arabinogalactan, 
providing an extraordinary lipid barrier. This barrier is responsible for many of the medically 
challenging physiological characteristics of tuberculosis, including resistance to antibiotics and 
host defense mechanisms.
13
 The composition and quantity of the cell wall components affect 
the bacteria’s virulence and growth rate. The peptidoglycan polymer confers cell wall rigidity 
and is just external to the bacterial cell membrane, another contributor to the permeability 
barrier of mycobacteria. Another important component of the cell wall is lipoarabinomannan, a 
carbohydrate structural antigen on the outside of the organism that is immunogenic and 
facilitates the survival of mycobacteria within macrophages.
14
  
         The cell wall is key to the survival of mycobacteria and a more complete understanding of 
the biosynthetic pathways, gene functions and the development of antibiotics to prevent 
formation of the cell wall are areas of great interest. 
 
Fig.3: Cell wall structure of Mycobacterium tuberculosis. 
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TARGET: L, D-TRANSPEPTIDASE 2 
        With multi-drug resistant cases of tuberculosis increasing globally, better antibiotic drugs 
and novel drug-targets are becoming an urgent need. Traditional β-lactam antibiotics that 
disrupt the D, D-transpeptidases are not effective against mycobacteria, in part because 
mycobacteria rely mostly on β-lactam insensitive L, D-transpeptidases for biosynthesis and 
maintenance of their peptidoglycan layer.  
 
Fig.4: Role of L,D-transpeptidase in peptidoglycan synthesis. 
        This reliance plays a major role in drug-resistance and persistence of Mycobacterium 
tuberculosis infections. The crystal structure at 1.7 Å resolution of the Mycobacterium 
tuberculosis L,D-transpeptidase LdtMt2 containing a bound peptidoglycan fragment provides 
information about catalytic site organization as well as substrate recognition by the enzyme. 
Based on structural, kinetic, and calorimetric data, a catalytic mechanism for LdtMt2 in which 
both acyl-acceptor and acyl-donor substrates reach the catalytic site from the same, rather than 
different, entrances has been proposed by Sabri B. Erdemli et al. Together, this information 
provides vital insights for the development of novel drugs targeting this validated yet 
unexploited enzyme.
15 
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MEDICINAL CHEMISTRY 
 
          Medicinal chemistry is best to be defined as an interdisciplinary research area 
incorporating different branches of chemistry and biology in the research for better and new 
drugs (Drug Discovery). In other words, medicinal chemistry is the science, which deals with the 
discovery and design of new and better therapeutic chemicals and development of these 
chemicals into therapeutic chemicals and development of these chemicals into new medicines 
and drugs.
16
 
 
DRUG DISCOVERY, DESIGN AND DEVELOPMENT
 
 
         The process of drug discovery is very complex and requires an interdisciplinary effort to 
design effective and commercially feasible drugs. The current scenario of development of new 
drugs needs no emphasis in light of the current global situation of health and disease. For the 
majority of time, drug discovery has been a trial-and-error process. Conventionally, the process 
of drug development has revolved around an almost blind screening approach, which was very 
time-consuming and laborious. The disadvantages of conventional drug discovery as well as the 
allure of a more deterministic approach to combat disease have led to the concept of "Rational 
drug design" in the 1960's. New understanding of the quantitative relationship between structure 
and biological activity ushered in the beginning of computer-aided drug design (CADD). With 
the introduction of integration and knowledge management solutions with the help of computers, 
a new era is beginning in drug discovery. The development cost will be cut by almost a third. 
The development times are reduced. At the onset, it is important to know what features an 
"ideal" drug should have. The drug 
i. must be safe and effective  
ii. should be well absorbed orally and bioavailable  
iii. metabolically stable and with a long half-life  
iv. nontoxic with minimal or no side effects 
v. should have selective distribution to target tissue.17 
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Lead identification 
 
         A lead is defined as a compound (usually a small organic molecule) that demonstrates a 
desired biological activity on a validated molecular target. To fulfill the criteria of what the 
industry considers a useful lead, the compound must exceed a specific potency threshold against 
the target (e.g., < 10 µM inhibition). The compounds used as potential leads could come from 
many sources. A majority of leads discovered in very recent programs are derived from a 
collection that is now referred to as a “library”. These may take the form of natural product 
libraries, peptides libraries, carbohydrates libraries, and/or small molecule libraries based on a 
variety of different molecular scaffolds. 
 
Lead optimization 
 
         Once a lead compound is established in the identification process, the medicinal chemist 
will work closely with molecular pharmacologists to optimize the desirable traits of the lead. 
This process can be relatively fast since history has taught the medicinal chemistry community 
how to manipulate molecules to improve activity. Starting with intuitive structural modification 
to the development of structure-activity relationship (SAR) and quantitative SAR (QSAR) one 
can gain tremendous information. 
 
COMPUTER-AIDED DRUG DESIGN
 
 
          Computer-aided drug design uses computational chemistry to discover, enhance, or study 
drugs and related biologically active molecules. The most fundamental goal is to predict whether 
a given molecule will bind to a target and if so how strongly. Molecular mechanics or molecular 
dynamics are most often used to predict the conformation of the small molecule and to 
Molecular mechanics or molecular dynamics are most often used to predict the conformation of 
the small molecule and to model conformational changes in the biological target that may occur 
when the small molecule binds to it. This provides semi-quantitative prediction of the binding 
affinity. Also, knowledge-based scoring function may be used to provide binding affinity 
estimates. These methods use linear regression, machine learning, neural nets or other statistical 
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techniques to derive predictive binding affinity equations by fitting experimental affinities to 
computationally derived techniques to derive predictive binding affinity equations by fitting 
experimental affinities to computationally derived interaction energies between the small 
molecule and the target.
18 
 
RATIONAL DRUG DESIGN
 
 
         Drug design is a process which involves the identification of a compound that displays a 
biological profile and ends when the biological profile and chemical synthesis of the new 
chemical entity are optimized. Drug designing is otherwise known as rational drug design and it 
is a method of finding new medications based on the biological receptors and target molecules. 
The objective of drug design is to find a chemical compound that can fit to a specific cavity on a 
protein target both geometrically and chemically.  
 
TYPES OF DRUG DESIGN
 
 Ligand-based drug design 
 Structure-based drug design 
 
Ligand-based drug design: 
 
         Ligand-based drug design is an indirect approach which relies on knowledge of other 
molecules that bind to the biological target of interest. These other molecules may be used to 
derive a pharmacophore model that defines the minimum necessary structural characteristics a 
molecule must possess in order to bind to the target. In other words, a model of the biological 
target may be built based on the knowledge of what binds to it and this model in turn may be 
based on the knowledge of what binds to it, and this model in turn may be used to design new 
molecular entities that interact with the target. 
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Structure-based drug design: 
 
            Structure-based drug design is a direct approach which relies on knowledge of the three 
dimensional structure of the biological target obtained through methods such as x-ray 
crystallography or NMR spectroscopy. If an experimental structure of a target is not available it 
may be possible experimental structure of a target is not available, it may be possible to create a 
homology model of the target based on the experimental structure of a related protein. Using the 
structure of the biological target, candidate drugs that are predicted to bind with high affinity and 
selectivity to the target may be designed using interactive and selectivity to the target may be 
designed using interactive graphics and the intuition of a medicinal chemist or various automated 
computational procedures to suggest new drug candidates.
19
 
 
DOCKING
 
 
           Docking is simply referred to the ability to position a ligand in the active or a designated 
site of a protein and calculate specific binding affinities. Ligand-protein docking has evolved so 
remarkably throughout the past decade that docking single or multiple small molecules to a 
receptor site is now routinely used to identify ligands. Optimal docking procedures need to be 
fast, generate reliable ligand geometries, rank the ligand conformation correctly (scoring), and 
thereby, estimate the binding energy. A number of studies have shown that docking algorithms 
are capable of finding ligands and binding conformations at a receptor site close to 
experimentally determined structures. These algorithms are equally applicable to the 
identification of multiple proteins to which a small molecule can bind. The application of this 
approach may facilitate the prediction of either unknown and secondary therapeutic target 
proteins or side effects and toxicity of particular drugs. In computational structure-based drug 
design, the evaluations of scoring functions are the cornerstones to the success of design and 
discovery. Many approaches have been explored to improve their reliability and accuracy, 
leading to three families of scoring functions. These are force-field-based, knowledge-based and 
empirical-based.
20
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SCORING FUNCTION
 
 
        Scoring functions are normally parameterized (or trained) against a data set consisting of 
experimentally determined binding affinities between molecular species similar to the species 
that one wishes to predict. 
 
Types: 
 
         1. Force field based - Force field affinities are estimated by summing the strength of 
intermolecular van der Waals and electrostatic interactions between all atoms of the two 
molecules in the complex. 
         2. Empirical - based on counting the number of various types of interactions between the 
two binding partners. Counting may be based on the number of ligand and receptor atoms in 
contact with each other or by calculating the change in solvent accessible surface area complex 
compared to the uncomplexed ligand and protein. These interactions terms of the function may 
include for example: hydrophobic-hydrophobic contacts, hydrophobic-hydrophilic contacts, 
number of hydrogen bonds, number of rotatable bonds immobilized in complex formation. 
         3. Knowledge-based (also known as statistical potentials) - based on statistical 
observations of intermolecular close contacts in large 3D databases which are used to derive 
"potentials of mean force". This method is founded on the assumption that close intermolecular 
interactions between certain types of atoms or functional groups that occur more frequently than 
one would expect by a random distribution are likely to be energetically favorable and therefore 
contribute favorably to binding affinity.
21
 
Absorption, Distribution, Metabolism and Excretion (ADME) analysis
 
         For a drug to be pharmacologically active and exert the action it should possess 
pharmacokinetic properties like Absorption, Distribution, Metabolism and Excretion. In the field 
of drug research and development many drug failures do occur, such that the drug may fail to 
undergo those properties satisfactorily. 
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       This has to be ruled out earlier in the process of drug discovery. Many in-vitro studies are 
more frequently used to evaluate ADME properties. Some computational methods (in silico 
tools) have been evolved to investigate the most suitable drug molecules. 
 
       In silico modeling serves for two main functions in predicting those (ADME) properties i.e, 
 Earlier investigation of designing compounds and compound libraries in order to 
reduce the risks at later. 
 Optimizes the screening and testing, most probably by focusing only the more active 
compounds. 
 A deep rooted knowledge in understanding the relationship of ADME parameters 
and the underlying (drug likeness property) molecular structural features to which it 
depends on. 
 It enhances in elaborating this session of interest to the area of posology where it 
gives information about the drug dosage and frequency. This in turn reflects issues 
on bioavailability, crossing various biological membranes like brain, ocular and 
dermal penetration. 
       These are the essential factors and criteria to look in, for a drug to be pharmacologically 
active and execute as the most successful clinical candidate in the pharmaceutical research. 
 
Prediction of ADME related parameters 
 
Absorption: 
 
        To investigate this property in silico model used simple parameters like log D (diffusion 
coefficient) and polar surface area are the descriptors for hydrogen bonding capacity and 
(partition coefficient) log P values should fall under the prescribed values as per the rule of 
thumb which determines the absorption. 
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Bioavailabilty: 
 
         Factors like size and shape of the molecule, lipophilicity and flexibility determines the 
bioavailability. 
 
Blood Brain Barrier Penetration: 
 
          In order for a drug to cross the blood brain barrier (molecule targeted to brain).Rule of 
thumb says that log P values should be closer to 2 with a molecular mass of <450 Da and or with 
a polar surface area (PSA) < 100 A are likely to possess. 
 
Dermal and Ocular Penetration: 
 
          For dermal and ocular route it should satisfy the existing parameters like (Partition 
coefficient) log P for aqueous solubility, molecular weight and molecular flexibility. 
 
Metabolism: 
 
          Various in silico approaches exist in evaluating the metabolism namely QSAR and 3D 
QSAR etc apart from those computational chemists have updated the structural details in the data 
bases and tools for predicting metabolism. Simultaneously it reveals the metabolic information 
as well as the toxicity related to the molecular fragments by which the drug molecule undergoes 
the metabolism.
60 
 
Evaluation of in silico toxicity: 
 
         Toxicity is one of the major criteria to be considered for a molecule to shine as a successful 
clinical candidate in the pharmaceutical research. About ~ 20 -40% of the drug failures fall under 
this category. Commercial in silico tools estimates toxicity and provides information by the use 
of QSAR (parameters and descriptors), scientific literatures and to some extent in abstracting 
issues from humans. 
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          In silico approaches like OSIRIS property explorer predicts carcinogenicity, mutagenicity, 
teratogenicity, immune toxicology, irritation, sensitization etc. In addition newly updated in 
silico tools helps in evaluating hepato, neuro and cardiotoxicity. 
 
CHALCONE
 
         
           Chalcone is the trivial name given to the α,β-unsaturated ketones obtained by condensing 
an aromatic aldehyde with an aryl methyl ketone in the presence of a base. They are designated 
structurally as Ar CH=CHC (O) Ar´ and their IUPAC name is 1, 3-Diphenyl-2-propene-1-one. 
The term “chalcone” was first used by Kostanecki.22 
        Chalcones are abundantly present in nature, from ferns to higher plants. During 1960‟s 
and 70‟s many chalcones have been reported to be isolated from the various parts of plants: 
buds, leaves, blossoms, heart wood, roots, seeds, flowers, and inflorescence. These compounds 
exist both in free and combined states either in the form of chalcones or glycosides 
respectively. These compounds have been found to carry many different substituents like 
methyl, isopentyl, methoxy and hydroxyl, which may be present either on ring A and/or ring B 
of the chalcone molecule. 
         Chalcones widely distributed in dilatory foods such as spices, tea, beer, fruits and 
vegetables and have been recently a subject of great interest for their pharmacological 
activities. According to Francisco A. et al. the major dietary source of dihydrochalcones is 
apples. The US FDA (Food and Drug Administration) and EU (European Union) have 
approved the neohesperidin dihydrochalcone to be used as sweetener in various foods like non-
alcoholic soft drinks, desserts and confectionery etc. at concentrations in the range 10-400 mg 
kg-1 (or mg l-1) or as a flavor modifier at concentrations of up to 5 mg kg-1.
23
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Chemistry of chalcones
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         In this structure, the group ─CH=CHC (=O) is known as the chalcone functionality or 
chalcone moiety or ketoethylenic group.  Due to this functionality, chalcones are also called α, 
β-unsaturated carbonyl systems or α,β-unsaturated ketones. The parent member of the chalcone 
series is benzylideneacetophenone. Other names given to chalcone are phenyl styryl ketone, β-
phenylacrylophenone, γ-oxo-α, γ- diphenyl-α-propylene, and α-phenyl-β-benzoylethylene. 
        Chalcones have a diverse array of groups on the two aromatic rings of 1, 3- Diaryl-2-
propene-1-one, as shown in the above structure, where the substituents R1 and R2 may be same 
or different and they may be present anywhere on the two rings. Moreover, R1 or R2 may not 
necessarily be a single substituent i.e. more than one substituent may be present on any of the 
two rings. Also, the two aromatic rings may be homocyclic or heterocyclic.
24
 
Claisen Schmidt Condensation Reaction
 
          
         The reaction between a ketone and a carbonyl compound lacking an alpha‐Hydrogen 
(Cross Aldol condensation) is called Claisen‐Schmidt condensation. These reactions are named 
after two of its pioneering investigators Rainer Ludwig Claisen and J. G. Schmidt, who independ
ently published on this topic in 1880 and 1881.
25
 
 
Mechanism 
 
        The first part of this reaction is an aldol reaction, the second part a dehydration,an 
elimination reaction (involves removal of a water molecule or an alcohol molecule). Dehydration 
may be accompanied by decarboxylation when an activated carboxyl group is present. The aldol 
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addition product can be dehydrated via two mechanisms; a strong base like potassium t-butoxide, 
potassium hydroxide or sodium hydride in an enolate mechanism or in an acid-catalyzed enol 
mechanism.
26
 
 
 
Fig 5: Mechanism of the Claisen Schmidt reaction 
 
Pharmacological Profile of Chalcones
 
        Chalcones, either natural or synthetic, are known to exhibit a broad spectrum of various 
biological activities. The presence of α, β-unsaturated carbonyl moiety as well as of substituted 
aromatic ring renders the chalcones biologically active
26
. Some substituted chalcones and their 
derivatives, including some of their heterocyclic analogues have been reported to possess 
strong biological properties which have been proved detrimental to the growth of microbes, 
tubercle bacilli, malarial parasites and intestinal worms
27
. Many chalcones have been claimed 
to be toxic to various animals and insects and have also shown inhibitory effects on several 
enzymes and herbaceous plants.
28 
A few major biological activities which have been reported 
to be associated with chalcones include: anti-inflammatory, antifungal, antiviral, antioxidant, 
antimalarial, antituberculosis, analgesic, anti- HIV and antitumor activities. Quinoline based 
chalcones have been reported to possess antimalarial activity.
29
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CHARACTERIZATION 
 
IR SPECTROSCOPY
 
        
        Infrared spectroscopy is certainly one of the most important analytical techniques. One of 
the great advantages of infrared spectroscopy is that virtually any sample in any state may be 
studied. 
        
         Infrared spectroscopy is a technique based on the vibrations of the atoms of a molecule. An 
infrared spectrum is commonly obtained by passing infrared radiation through a sample and 
determining what fraction of the incident radiation is absorbed at a particular energy. The energy 
at which any peak in an absorption spectrum appears corresponds to the frequency of a vibration 
of a part of a sample molecule.
30
 
         
         Infrared spectroscopy is used to obtain information on the molecular structure of the 
sample. The infrared spectrum is related to the vibrations of molecules and is unique for each 
compound, like a fingerprint for a person. 
        
         The possible characteristic bands obtained in IR spectroscopy are: 
 3300 - 3540 cm-1 N-H Stretching vibration 
 3650 - 3200 cm-1 O-H stretching vibration 
 1690 - 1630 cm-1 C=N stretching vibration 
 2960 - 2850 cm-1 C-H aliphatic stretching vibration 
 3100 - 3000 cm-1 C-H aromatic stretching vibration.31 
 
NMR SPECTROSCOPY
 
       
          Nuclear magnetic resonance spectroscopy is one of the most important characterization 
method.  The NMR phenomenon is based on the fact that nuclei of atoms have magnetic 
properties that can be utilized to yield chemical information.
32
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          The NMR spectrum proves to be of great utility in structure elucidation because the 
properties it displays can be related to the molecular structure. The chemical shift of a particular 
nucleus can be correlated with its chemical environment, the scalar coupling (or J-coupling) 
indicates an indirect interaction between individual nuclei, mediated by electrons in a chemical 
bond, and, under suitable conditions, the area of a resonance is related to the number of nuclei 
giving rise to it.
33
 
           The possible characteristic peaks obtained are: 
 Aromatic and Heteroaromatic proton 6 – 8 δ 
 Phenolic proton 4 – 12 δ 
 Aliphatic proton 1.5 – 4.5 δ 
 
 
MASS SPECTROSCOPY
 
        
            Mass spectrometry is a powerful analytical technique that is used to identify unknown 
compounds, to quantify known compounds, and to illuminate the structure and chemical 
properties of molecules. Detection of compounds can be accomplished with very minute 
quantities
34
. 
      
            Atoms or molecules are passed into a beam of high-speed electrons. The high-speed 
electrons knock electrons off the atoms or molecules being analyzed and change them to positive 
ions. The applied electric field then accelerates these ions through a magnetic field, which 
deflects the paths of the ions. The most massive ions are deflected the smallest amount, which 
causes the ions to separate. The gas phase ions are sorted in the mass analyzer according to their 
mass-to-charge (m/z) ratios and then collected by a detector. In the detector the ion flux is 
converted to a proportional electrical current. The data system records the magnitude of these 
electrical signals as a function of m/z and converts this information into a mass spectrum. It is 
used to identify, quantify, and elucidate structures of chemical compounds.
35 
 
 
 
Introduction  
 
Department of Pharmaceutical chemistry, Madras medical college. Page 22 
 
ANTITUBERCULAR ACTIVITY
 
          
           From the earlier to the present status, tuberculosis is existing with (extreme & multi-drug 
resistance), increased susceptibility in transmission, their complex pathophysiology leading to 
higher risks of infections to other organs and increases the rate of mortality. So essentially there 
is an urgent and rapid need of drugs to combat this disease, which in turn it is screened for anti 
tuberculosis activity. 
        
           The following methods are used for the invitro evaluation of antitubercular activity. 
 
 Resazurin Micro Plate Assay(REMA) 
 Nitrate Reductase Assay(NRA) 
 Micro Plate Alamar Blue Assay( MABA) 
 Middle Brook 7H11 Agar Dilution Assay 
 BACTEC System 
 Luciferase Reporter Phage Assay.36 
    
    The synthesized compounds can be evaluated for anti tubercular activity by any of the above 
methods. 
 
MICROPLATE ALAMAR BLUE ASSAY
 
       
      The Microplate alamar blue assay (MABA) method was used to evaluate antitubercular 
activity of synthesized compounds against mycobacterial strain Mycobacterium tuberculosis 
H37Rv. The medium used for this evaluation is 7H9GC media. 
 
Principle
 
 
        Resazurin is purple in color. Resazurin reduces in two steps, irreversibly to resorufin and 
then reversibly to dihydroresorufin, providing color changes from purple to pink to colorless. 
The tubercle bacteria reduce resazurin which causes disappearance in purple color. The synthetic 
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compounds cause reoxidation which is pink in colour. The color intensity is measured in 
fluorimeter.
37
 The percentage inhibition is defined as 
 
                              %   Inhibition    =                    Test well fluorescence                p 
                                                                   Mean fluorescence of triplicate wells 
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Method
 
 
          Antitubercular activity was evaluated against Mycobacterium tuberculosis H37Rv using 
Micro plate alamar blue assay (MABA) method. Antitubercular susceptibility test was performed 
in black, clear bottomed, 96-well micro plates in order to minimize background fluorescence. 
Initial drug dilutions were prepared in dimethylsulfoxide and subsequent two fold dilutions were 
performed in 0.1 ml of 7H9GC media in the micro plates. 100ml of 2000 CFU/ ml of M. 
tuberculosis H37Rv were added to each well of 96 well microtitre plate containing test 
compounds. Three control well plates containing drug and medium, bacteria and medium and 
medium only were also prepared. All microtitre plates were incubated at 37°C for seven days. At 
day 7 of incubation Alamar blue dye solution (20 μl Alamar blue solution and12.5 ml of 20% 
Tween 80) was added to all the wells and plates were re-incubated at 37°C for 24 h. 
Fluorescence was measured in a fluorimeter and MIC was determined.
38 
 
Advantages 
 
 It has accurate time-course measurement 
 It has high sensitivity and linearity 
 It involves no cell lysis 
 It is ideal for use with post measurement functional assays 
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 It is flexible as it can be used with different cell models 
 It is scalable and can be used with fluorescence and/or absorbance-based 
instrumentation platforms 
 Finally, it is non-toxic, non-radioactive and is safe for the user. 
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AIM 
 
The aim of this project is to develop potential antimycobacterial agents. 
 
OBJECTIVES 
 
The objective of the project is to design and synthesize some compounds which will act on L, D 
Transpeptidase 2 and inhibit the cell wall synthesis of M.tuberculosis. 
 
THE PLAN OF WORK 
 
 Design of L, D Transpeptidase 2 inhibitors by docking studies 
 
 Insilico Prediction of Drug Likeness and Toxicity 
 
 Laboratory synthesis of the top G score compounds 
 
 Characterization of the synthesized compounds by 
 
 Infrared Spectroscopy 
 Nuclear Magnetic Resonance Spectroscopy 
 Mass Spectroscopy 
 
 In-vitro anti tubercular activity of synthesized compounds. 
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The whole study was carried out according to this flow chart. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identification of basic nucleus 
Structural modification of the basic Nucleus 
Docking the molecule in the target protein 
Optimization of the highly Interacting molecules 
Top G score compounds selected 
Synthesis 
Characterization-Spectroscopy (IR, NMR, MASS) 
In-vitro anti tubercular activity (MABA) 
In-Silico investigation of Drug likeness and Toxicity 
 
  
 
 
 
Review of   Literature 
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LITERATURE REVIEW 
 
A) Reviews related to the antimycobacterial activity of chalcones 
 
Louise Domeneghini Chiaradia et al
46
., synthesized 38 new chalcones for their anti-tubercular 
activity by targetting mycobacterium enzyme phosphotyrosine phosphatese. Out of the 38, 5 
compounds shows good active against Mycobacterium tuberculosis PtpA at the concentration 
range  of 5–60µg/ml.  
  
OR1
O O
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CH3
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Antitubercular activity 
 
 
Shahar Yar et al
47
., synthesized a novel series of eleven chalcones, which were tested for 
antimycobacterial activity against M. tuberculosis H37RV using a BACTEC- 460 radiometric 
system. Among the eleven chalcones, only six were found to be active. The compounds 
exhibited largest efficacy and displayed 90% inhibition at MIC ≈ 6.25 μg/ml. 
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Antitubercular activity 
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P M Sivakumar et al
48
., synthesized and screened a series of chalcones for their anti tubercular 
activity. Twenty three chalcones were synthesized and were evaluated for antimycobacterial 
activity. Ortho chloro substitutions at A and B-ring was found to  favour activity. Methylsulfonyl 
chalcones exhibit very good activity. 
OR1
R2
R3
R4
R5
R6 
Antitubercular activity 
 
Jahirul Islam Talukdar and Monica Kachroo
49
., synthesized chalcones and tested for its 
Antitubercular and antibacterial activity. It was found that all the compound possessed 
antibacterial activity, on the other hand, the compound N-{4-[3-(2,4-dimethoxy-phenyl)-
acryloyl]-phenyl}-4- methoxy benzamide exhibited  antitubercular activity at concentration of 25 
µg/ml whereas all other derivatives of the series exhibited activity at a concentration of above 50 
µg/ml. 
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Antibacterial and Anti tubercular activity 
 
Dr. Mrunmayee Toraskar et al
49
., synthesized thiophene derivatives of chalcones. The 
compounds were evaluated for in vitro anti-fungal, anti-tubercular and anti-oxidant activity. All 
the synthesized compounds showed very good in vitro anti-fungal activity against C. albicans by 
using fluconazole as standard. Compounds with electron donating groups on the aldehydic 
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phenyl ring showed very good anti-tubercular activity against mycobacterium tuberculosis. 
Compounds with substituted 4-methoxy group at phenyl ring showed good anti- oxidant activity 
may be due to its electron donating ability. 
NH
O
NH
O
ArS
 
Antifungal, Antimycobacterial and Antioxidant activity 
 
B) Reviews related to other biological activities of chalcones 
 
Seema I. Habib et al
51
., synthesized and screened a series of chalcones for their antimicrobial 
activity. The screening of antimicrobial data revealed that compounds with pyridine nucleus 
showed much activity than pyrrole. 
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Antimicrobial activity 
 
Susanne et al.
56
, synthesized the 3′- coumaroyl-2′, 4, 4′-trihydroxy-6′-methoxychalcone, were 
structurally derived from helichrysetin. This compound showed the highest cytotoxic activity 
against HeLa cells with an IC50 value of 7.3 ± 0.4 μM. Anti-oxidative effects were determined 
in the ORAC assay and revealed very strong activity for the compound given below. 
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Anti-oxidant activity 
 
Bathelemy Ngamenil et al
52
., synthesised and evaluated anticancer activity for O-allylchalcone 
derivatives. The series of new O-allylchalcone derivatives prepared by a Claisen-Schmidt 
condensation reaction have good ability to kill tumor cells in vitro. 
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Anticancer activity 
 
Won et al
53
., synthesized chalcones and screened for their anti-inflammatory activity. This 
synthesised chalcones has the ability to inhibit chemical mediators released from mast cells, 
neutrophils, macrophages. 
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S
 
Anti-inflammatory activity 
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Domínguez et al
54
., reported phenylurenyl chalcone derivatives, with substitution in ring B 
(IC50 = 1.76-10 μM) as potent growth inhibitors against in vitro cultured P.falciparum. 
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Antimalarial activity 
 
Carla et al
55
., showed a new set of sulfonamide 4- methoxychalcone derivatives were 
synthesized and which shown antileishmanial activity against Leishmania braziliensis 
promastigotes and intracellular amastigotes and determined its cell toxicity profile. Interestingly 
all compounds presented a concentration dependent antileishmanial profile and the benzylamino 
derivative showed a biological activity better than pentamidine. 
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Antileishmanial activity 
 
Dong et al
56
., studied the series of prenylated flavonoids. According to the estimated result, 
eleven molecules were selected and synthesized. Their vasodilatory activities were determined 
experimentally in rat aorta rings that were pretreated with phenylephrine (PE). Structure–activity 
relationship (SAR) analysis revealed that flavanone derivatives showed the most potent 
activities, while flavone and chalcone derivatives exhibited medium activities. 
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Vasodilatory activity 
 
 
C) Review related to the target 
 
Sabri B. Erdemli et al
57
  studied that the  traditional β-lactam antibiotics that disrupt the D,D-
transpeptidases are not effective against mycobacteria as mycobacteria rely mostly on β-lactam 
insensitive L,D-transpeptidases for biosynthesis and maintenance of their peptidoglycan layer. 
This plays a major role in drug-resistance and persistence of infections. The crystal structure at 
1.7 Å resolution of the Mtb L,D-transpeptidase LdtMt2 contains a bound peptidoglycan fragment 
which provides information about catalytic site organization as well as substrate recognition by 
the enzyme. Based on the structural, kinetic, and calorimetric data, a catalytic mechanism for 
LdtMt2 has been proposed. 
 
Soumya De and Lawrence P. McIntosh
58
 investigated the structural and dynamic basis for the 
unexpected inhibition of peptidoglycan crosslinking L, D transpeptidases by carbapenam 
antibiotics. 
 
Dominic Both et al 
59 
studied the crystal structure of the protein and summarized that the 
transpeptidase LdtMt2 catalyzes the formation of the cross-links characteristic of the 
peptidoglycan layer in the Mycobacterium tuberculosis cell wall. Bioinformatics analysis 
suggests that the extramembrane part of the enzyme consists of three domains: two smaller 
domains (denoted as A and B domains) and a transpeptidase domain (the C domain) at the C-
terminus. The crystal structures of two fragments comprising the AB domains and the BC 
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domains have been determined. Combining the structures of the two fragments provides a view 
of the complete three-domain extramembrane part of LdtMt2 and shows that the protein extends at 
least 80– 100 A ° from the plasma membrane into the peptidoglycan layer and thus defines the 
maximal distance at which crosslinks are formed by this enzyme.  
 
D) Reviews related to synthesis of Chalcones 
 
Claisen Schmidt condensation
42 
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Arshi Naqvi et al
43
., synthesised chalcones by stirring method using 50% NaOH. 
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Nitin Kumar et al
44
., synthesised chalcones by using 40% NaOH. 
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E) Reviews related to the evaluation of anti tubercular activity by MABA 
 
1) Scott G.Franzblau et al36, studied MIC determination by MABA. A colorimetric, 
microplate- based Alamar blur Assay (MABA) method was used to determine the MICs 
of Isoniazid, rifampin, streptomycin and ethambutol for 34 Peruvian Mycobacterium 
tuberculosis isolates and the H37Rv strain by using bacterial suspensions prepared 
directly from media. The MABA is a simple, rapid, low-cost, appropriate technology 
which does not require expensive instrumentation and which makes use of a nontoxic, 
temperature-stable reagent 
 
2) Sephra N.Rampresad et al37 studied the various applications of Alamar blue as an 
indicator. Alamar Blue is an important redox indicator that is used to evaluate metabolic 
function and cellular health. The Alamar blue bioassay is being utilized to access cell 
viability and cytotoxicity in a range of biological and environmental system and in a 
number of cell types including bacteria, yeast, fungi,protozoa. 
 
 
3) Jose de Jesus Alba-Romero et al38 applied the Alamar Blue assay to determine the 
susceptibility to anti-tuberculosis pharmaceuticals. The results showed that the MABA 
test is fast and easy to apply. It is a very reliable method of determining the drug 
susceptibility to pharmaceuticals. 
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MATERIALS AND METHODS 
1. DRUG DESIGN 
           In this research Glide
® 
(grid based ligand docking with energetics) program was used for 
screening a large number of compounds. Glide automatically searches for favorable interactions 
between ligand molecule and the receptor in different conformations. Docking procedure using 
glide program includes the following steps, 
1. Protein preparation  
2. Receptor grid generation 
3. Ligand preparation 
4. Ligand docking 
5. Visualizing docking poses 
 
Protein preparation
 
          Protein data bank (PDB) file, which is the crystallized structure of the receptor/protein is 
imported from Protein Data Bank with the following PDB id: 3VAE(L,D Transpeptidase 2), 
resolution 2.8Å, preprocessed involving addition of hydrogen, assigning bond order, finding 
overlaps, creating zero order bond to metals, creating disulfide bonds, Filling missing side chains 
and loops using prime option. The water molecules, co-factors and unwanted chains were 
deleted. And the energy minimization has been done so that it will be ready for grid generation. 
The PDB file was selected based on its species, X-ray crystallography or NMR spectroscopy, 
resolution value, external ligand and presence co-factos.
39 
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Fig 6: 3VAE 
Receptor Grid Generation 
       Once the protein has been prepared, the grid has to be generated which is the critical 
process, It includes defining the active site in the protein (receptor). The prepared protein file 
was loaded into the workspace the active site residues were found and picked and the length for 
docking the ligand to the protein is given as 10Å. The grid was generated on giving start in the 
grid generation tab. The grid output file obtained as zip file format was utilized for further 
docking process. 
Ligand Preparation
 
       Ligand preparation process consists of a series of steps that include conversions, applying 
corrections to the structures drawn, generating variations on the structure, eliminating unwanted 
structures and optimizing the structures. 
      Variations on the structure can be made by addition of hydrogen atoms, removal of unwanted 
molecules, neutralizing charged groups. The structure can be optimized by generating ionization 
states, generating tautomers, filtering the structure on the basis of Lipinski’s rule of five.  
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Ligand docking  
        After the generation of the grid, the prepared ligands were docked to see the interaction with 
the active site of the protein. There were hydrophobic, hydrophilic and Vanderwaal’s interaction. 
The strength of the interaction was different for different ligand molecules. During the docking 
procedure, conformation of the ligand was retained and extra precision (xp) mode was selected. 
In this procedure the following constraints like active site and rotatable groups have been 
checked. Around 1000 molecules were docked and these with best scores were taken for 
synthesis and screening purpose.
41 
 
Visualization of the docking poses 
        Once the molecules were docked, then they were visualized for interactions, score and some 
other parameters like log P value and ionization value. There were interactions like hydrogen 
bonding, hydrophobic interaction, Vanderwaal’s interaction between the receptor and the ligand. 
Based on the interaction and score obtained, the molecules were categorized into hit and flop. 
The hit molecules were accounted for synthesis and screening. 
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2. IN-SILICO SCREENING OF DRUG LIKENESS 
                 For a drug to be pharmacologically active and exert action it should posses 
pharmacokinetic properties like absorption, distribution, metabolism and excretion. Many drug 
failures occur due to unfavourable ADME properties in the field of drug research and 
development. This has to be ruled out earlier in the process of drug discovery. Some 
computational methods (in silico tools) have been evolved to investigate the most suitable drug 
molecules before synthesis. 
 
                 Lipinski's rule of five also known as the Pfizer's rule of five is a rule to evaluate 
drug likeness. It is used to predict whether a molecule is likely to be orally bio-available or to 
evaluate drug likeness.
61 
 
Lipinski’s rule 
 
                   This rule is used to predict whether a molecule is likely to be orally bio-available or 
to evaluate drug likeness. The rule was formulated by Christopher A. Lipinski in 1997.The rule 
states that for drug likeness the molecule should have the following properties: 
 Molecular weight less than 500 Daltons 
 Calculated log P value less than 5 
 Less than 10 hydrogen bond acceptor groups( eg.-O-, -N-,etc) 
 Less than 5 hydrogen bond donor groups (eg. NH, OH, etc) 
 Less than 10 rotatable bonds 
 
                   The designed and docked molecules are screened in silico using Molinspiration 
Cheminformatics Software to evaluate drug likeness. This tool is quick and easy to use. It can 
be accessed online for calculation of important molecular properties such as logP, polar surface 
area, number of hydrogen bond donors and acceptors as well as prediction of bioactivity score 
for the most important drug targets like GPCR ligands, kinase inhibitors, ion channel modulators, 
nuclear receptors.
62 
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3. IN SILICO TOXCITY PREDICTION 
              Toxicity screening is done insilico using OSIRIS Property Explorer. It is a web based 
software available on the Organic Chemistry Portal
63
. Using this prediction tool, mutagenicity, 
tumorogenicity, skin irritancy, and reproductive effects can be calculated. The prediction 
properties depends on a precompiled set of structure fragment that gives rises to toxicity alerts, if  
they are found in the structure currently drawn. These fragment lists is created by rigorously 
shredding all compounds in the data base known to be active in a certain toxicity class. During 
the shredding any molecule is first cut at every rotatable bonds leading to a set of core 
fragments.
64
 Osiris software is used to calculate various drug relevant properties of chemical 
structures. The results are colour coded. The green colour represents that the compound is non-
toxic. Yellow and red colour indicates moderate and severe toxicity of the chemicals 
respectively. 
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4. SYNTHETIC METHODOLOGY 
REACTANT PROFILE 
 
1. ALPHA ACETYL BUTYROLACTONE 
                 Structure:  
                     O
O
CH3
O
    
                 Synonym: 3-acetyldihydrofuran-2(3H)-one 
                 Molecular Formula: C6H8O3 
                 Molecular Weight: 128.12 
                 Description:  Colourless to light yellow liquid 
                 Boiling Point: 107°C 
 
2. 2-CHLORO 5-NITRO BENZALDEHYDE 
                 Structure:  
                     
Cl
N
+
O
-
O
O
H
    
                 Synonym: 2- chloro-5-nitro benzaldehyde 
                 Molecular Formula: C7H4ClNO3 
                 Molecular Weight: 185.56 
                 Solubility: Soluble in DMSO,chloroform, acetonitrile. 
                 Description:  Light yellow to beige yellow crystalline powder 
                 Melting Point: 76°C 
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3. Para- DIMETHYL AMINO BENZALDEHYDE 
                 Structure:  
                     
O
N
CH3CH3
H
    
                 Synonym:  4- (dimethylamino) benzaldehyde 
                 Molecular Formula: C9H11NO 
                 Molecular Weight: 149.18 
                 Solubility: Soluble in chloroform,acetonitrile,hot ethanol.Slightly soluble in water. 
                 Description:  White crystalline powder 
                 Melting Point: 73°C 
 
SYNTHESIS
42-44 
 
O
O
Ar
O
O
O
CH3
O
+
40% KOH
Stirring, r.t
O
Ar
alpha acetyl butyrolactone aldehyde Chalcone  
 
 
                Ar- 
                       
N
CH3
CH3
  ,   Cl
N
+
O
-
O
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PROCEDURE
 
 
               A mixture of alpha acetyl butyrolactone (0.01 moles) and aryl aldehyde (0.01 moles) 
was stirred in ethanol (15 ml) and then an aqueous solution of potassium hydroxide (40%, 15 ml) 
was added to it. The reaction mixture was stirred at room temperature for 6 hours.
 
The 
completion of the reaction was monitored by TLC. After the completion of the reaction, the 
reaction mixture was poured into cold water and acidified with hydrochloric acid (10%). The 
solid that separated was filtered and dried. It was recrystallised with ethanol.
42,43 
 
RECRYSTALLISATION 
 
                To the synthesized compound, warm ethanol was added and it was heated. The hot 
solution was filtered and the filtrate was collected in a china dish and allowed to cool. On 
cooling, crystals appeared. 
 
CHARACTERIZATION 
 
A) MELTING POINT 
                 The melting point of the synthesized compound was determined by one end open 
capillary method.  
 
B) THIN LAYER CHROMATOGRAPHY 
The reactants and products were dissolved in ethanol. It was spotted on the TLC plate. 
 
Stationary phase: Pre-coated Silica gel GF plates 
Mobile phase: Benzene:Chloroform:Ethanol (5:4:1) 
Detection: UV chamber 
 
A single principle spot for the product and the absence of secondary spots and spots for parent 
compounds confirmed the purity of the compound. 
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C) IR SPECTROSCOPY 
                  IR Spectroscopy helps to ascertain the presence and absence of the functional group. 
The synthesized compound was made into a pellet with potassium bromide by pressed pellet 
technique using pellet press (Model No: M15). The pellet was mounted on the pellet disc and 
percentage transmittance was recorded in ABB IR Spectrophotometer (Model No: MB 3000). 
 
D) NMR SPECTROSCOPY 
               Proton NMR Spectroscopy helps us to study the number of equivalent protons and their 
environment thereby we can ascertain the structure of the molecule. The NMR spectra were 
recorded on 300 MHz BRUKER Advance III NMR Spectrometer. DMSO was used as solvent. 
 
E) MASS SPECTROSCOPY 
                 Mass Spectroscopy enables us to establish the molecular mass of the compound. The 
mass spectra of the synthesized compounds were recorded in Q-Tof-Mass Spectrometer (Q-Tof 
micro hybrid quadrupole time of flight mass spectrometer) with electrospray ionization (ESI) and 
in JEOL GCMATE II GC-MS. 
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5. IN VITRO ANTITUBERCULAR ACTIVITY 
 
Anti-TB activity using Alamar Blue Dye 
 
 
 PROCEDURE 
 
1) The anti mycobacterial activity of compounds were assessed against M. tuberculosis 
using microplate Alamar Blue assay (MABA). 
2) This methodology is non-toxic, uses a thermally stable reagent and shows good 
correlation with propotional and BACTEC radiometric method. 
3) Briefly, 200µl of sterile deionzed water was added to all outer perimeter wells of sterile 
96 wells plate to minimize evaporation of medium in the test wells during incubation. 
4) The 96 wells plate received 100 µl of the Middlebrook 7H9 broth and serial dilution of 
compounds were made directly on plate. 
5) The final drug concentrations tested were 100 to 0.2 µg/ml. 
6) Plates were covered and sealed with parafilm and incubated at 37ºC for five days. 
7) After this time, 25µl of freshly prepared 1:1 mixture of Alamar Blue reagent and 10% 
tween 80 was added to the plate and incubated for 24 hrs.  
8) A blue color in the well was interpreted as no bacterial growth, and pink color was scored 
as growth.  
9) The MIC was defined as lowest drug concentration which prevented the color change 
from blue to pink.
45
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RESULTS AND DISCUSSION 
 
1. DRUG DESIGN 
The designed molecules were docked against the target 3VAE after the active site on the protein 
was selected using Sitemap function. For perfect docking of the ligand into the cavity of the protein 
having active site, extra precision mode molecular docking was executed. During the docking procedure 
different poses of the ligand were generated. The ligands were docked in different poses. The best docked 
pose was selected based on the G.Score generated and the interactions between the protein and the ligand. 
Hydrogen bond interactions are seen between the compounds and the active site. Hydrophobic 
interactions are also seen. 
 
DOCKING SCORE OF THE COMPOUNDS AGAINST 3 VAE 
 
1. SR1: G Score: -7.04 kcal/mol 
 
O
O
O
N
+
O
-
O
Cl
 
 
2. SR2: G Score: -7.64 kcal/mol 
 
O
O
O
N
CH3
CH3
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DOCKING SCORE OF THE STANDARD DRUGS AGAINST 3VAE 
 
 
NH2
NH
O
N
                                               O
NH2
NN
 
                           Isoniazid            Pyrazinamide 
                    G.Score: -5.1 kcal/mol     G.Score: -4.3 kcal/mol 
 
 
 
OH
O
N N
NH
F
O
 
 
                                                                  Ciprofloxacin                   
  G.Score: -7.0 kcal/mol 
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COMPOUNDS DOCKED AGAINST PROTEIN 3VAE 
 
 
Fig 7: SR1 docked against 3VAE 
 
 
                                               Fig 8: SR 2 docked against 3VAE 
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INTERACTIONS BETWEEN THE COMPOUNDS AND THE PROTEIN 
 
         Key:                                     
  
 
Fig 9: Interactions of SR 1 with 3VAE 
 
Fig 10: Interactions of SR 2 with 3VAE 
Hydrophobic Interaction 
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2. IN-SILICO SCREENING OF DRUG LIKENESS 
             The compounds were screened for drug likeness by using Molinspiration 
Cheminformatics Software. On screening it was found that the ADME parameters were within 
the range. 
 
 
 
Molinspiration property engine 
v2013.09 
 
miLogP         1.435 
TPSA           89.2 
natoms         20.0 
MW             295.678 
nON            6 
nOHNH          0 
nviolations    0 
nrotb          4 
volume         234.871 
 
 
 
 
Fig 11: Screenshot of SR 1 screening of drug likeness in Molinspiration 
 
 
 
Molinspiration property engine 
v2013.09 
 
miLogP         1.152 
TPSA           46.614 
natoms         19.0 
MW             259.305 
nON            4 
nOHNH          0 
nviolations    0 
nrotb          4 
volume         243.907 
 
 
 
Fig 12: Screenshot of SR 2 screening of drug likeness in Molinspiration 
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3. IN SILICO TOXCITY PREDICTION 
 
              In silico toxicity prediction was done using OSIRIS Property Explorer. This software is 
available for access in the Organic Chemistry Portal. Using this prediction tool, mutagenicity, 
tumorogenicity, skin irritancy, and reproductive effects were calculated. The results were colour 
coded. The green colour represents that the compound is non-toxic. Yellow and red colour 
indicates moderate and severe toxicity of the chemicals respectively. 
 
 
                                           
 
   Fig 20: Toxicity prediction for SR 1                           Fig 21: Toxicity prediction for SR 2 
 
 
The compound SR 1 is predicted to have moderate skin irritancy and mutagenic effect where as 
the compound SR 2 is predicted to have severe mutagenic and tumorogenic effect.  
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4. SYNTHESIS AND CHARACTERIZATION 
 
         The synthetic scheme was drawn for the hit compounds from docking and the procedure 
for synthesis was collected from literature. The necessary chemicals of laboratory grade were 
procured and synthesis was carried out after the optimization of the reaction conditions. Products 
were obtained with a yield of about 82 % and then recrystallised. The physical properties such as 
appearance, solubility, melting point were recorded and uncorrected. 
 
Analytical Data: Compound SR1 
 
O
O
O
Cl
N
+
O
-
O
 
3-[(2E)-3-(2-chloro-5-nitrophenyl)prop-2-enoyl]dihydrofuran-2(3H)-one 
 
 
S. No Properties 
1. Description Yellowish white crystals 
2. Molecular Formula C13H10ClNO5 
3. Molecular Weight 295.67 
4. Melting Point 134 ºC 
5. Solubility Partially soluble in ethanol and methanol, fully soluble in DMSO, 
insoluble in water 
 
Table No 3: Physical properties of SR 1 
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IR SPECTROSCOPY  
 
 
                
Fig 13: IR Spectra of SR 1 
 
Compound IR Absorption region (cm
-1
) Interpretation 
 
SR 2 3116 cm
-1
       
3070 cm
-1          
 
2923 cm
-1 
      
1643 cm
-1          
 
1751 cm
-1 
      
1458 cm
-1
       
1350 cm
-1
      
Aromatic C-H stretching  
Alkene C-H stretching 
Aliphatic C-H stretching 
Aliphatic C=C stretching 
Aliphatic ketone (C=O) stretching 
Aromatic C=C stretching 
Nitro N=O stretching 
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NMR SPECTROSCOPY 
 
 
 
Fig 14: NMR Spectra of SR 1 
 
 
Compound 
1
H NMR Data 
SR 1 δ 2.54-2.56 (m, 5H, Heterocyclic CH2) 
δ 4.42-4.45 (d, 1H, Vinylic CH) 
δ 4.46-4.47 (d, 1H, Vinylic CH) 
δ 7.60-8.52 (m, 3H, Aromatic CH) 
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MASS SPECTROSCOPY 
 
 
 
Fig 15: Mass Spectra of SR 1 
 
 
Compound Mol. formula / Mol. Wt  calculated m/e value &  
Relative abundance 
SR 1 C13H10ClNO5 /295.67 
 
295.47 (M
+
) 
160.25 (B) 
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Analytical Data: Compound SR2 
 
O
O
O
N
CH3
CH3
 
 
3-{(2E)-3-[4-(dimethylamino) phenyl] prop-2-enoyl}dihydrofuran-2(3H)-one 
 
 
S. No Properties 
1. Description Yellowish orange crystals 
2. Molecular Formula C15H17NO3 
3. Molecular Weight 259.30 
4. Melting Point 118 ºC 
5. Solubility Soluble in ethanol and other organic solvents, insoluble in water 
 
 
Table No 4: Physical properties of SR 2 
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IR SPECTROSCOPY  
 
 
 
Fig 16: IR Spectra of SR 2 
 
 
Compound IR Absorption region (cm
-1
) Interpretation 
 
SR 2 3093 cm
-1
 
3055 cm
-1
 
2916 cm
-1
 
1774 cm
-1
 
1643 cm
-1
 
1434 cm
-1
 
 
Aromatic C-H stretching 
Alkene C-H stretching 
Aliphatic C-H stretching 
Aliphatic ketone (C=O) stretching 
Aliphatic C=C stretching 
Aromatic C=C stretching 
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NMR SPECTROSCOPY  
 
 
 
Fig 17: NMR Spectra of SR 2 
 
Compound 
1
H NMR Data 
SR 2  δ 2.43-3.20 (m, 3H, Heterocyclic CH2) 
δ 3.32-3.35 (s, 6H, Aliphatic CH3) 
δ 6.59-6.98 (d, 1H, Vinylic CH) 
δ 7.41-7.95 (m, 3H, Aromatic CH) 
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MASS SPECTROSCOPY  
 
  
 
Fig 18: MASS Spectra of SR 2 
  
Compound Mol. formula / Mol. Wt  calculated m/e value &  
Relative abundance 
SR 2 C15H17NO3 / 259.30 259 (M
+
)
 
 
252 (B) 
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2. IN VITRO ANTITUBERCULAR ACTIVITY 
 
      The anti tubercular activity of the synthesized compounds was determined by MABA method. 
The organism used is mycobacterium tuberculosis. The pathogen tested was susceptible to all the 
synthesized compounds and the MIC for all the compounds was found. The data pertaining to those 
observations are tabulated below and the growth of the organism is shown in the figure below. It was 
observed from the study that the MIC of all the synthesized compounds showed anti mycobacterial 
activity at 50 µg/ml and 100 µg/ml. The inhibition was compared with Pyrazinimide (3.125 µg/ml), 
Streptomycin (6.25 µg/ml), Ciprofloxacin (3.125 µg/ml). 
 
Sl.No Samples 100 
µg/ml 
50 
µg/ml 
25 
µg/ml 
12.5 
µg/ml 
6.25 
µg/ml 
3.12 
µg/ml 
1.6 
µg/ml 
 
0.8 
µg/ml 
1. SR1 S S R R R R R R 
2. SR2 S R R R R R R R 
 
Table No 6:   Anti tubercular activity results in µg/ml. 
NOTE: 
S-Sensitive, R-Resistant 
Strain Used: M.tuberculosis(H37 RV Strain) 
 
Standard values: 
Pyrazinimide- 3.125 µg/ml, Streptomycin-6.25 µg/ml, Ciprofloxacin- 3.125 µg/ml 
 
 
 
 SR2 
 
 
 SR1  
 
Fig 19: Invitro Antitubercular Activity by MABA 
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SUMMARY 
 
 L, D Transpeptidase 2 is a crucial enzyme present in the cell wall of Mycobacterium 
tuberculosis H37Rv. It is a peptidoglycan binding protein. It plays a vital role in the cell 
wall synthesis. 
 This enzyme was chosen as the target for the drug design study after detailed literature 
review. 
 A database of 100 molecules with potential to inhibit the target (PDB id: 3VAE) was 
chosen by altering the lead butyrolactone nucleus. 
 The designed molecules were docked against the chosen target using GLIDE® (Grid 
Based Ligand Docking with Energetics). 
 From among the docked molecules, 2 molecules with good Glide score were chosen for 
further laboratory synthesis. Drug likeness was predicted insilico before proceeding for 
synthesis.  The reaction conditions were optimized. 
 The synthesized compounds were labeled as SR1 and SR2 and recrystallised. 
 The purity of the synthesized compounds was assessed by melting point and TLC. The 
synthesized compounds were characterized by Infrared Spectroscopy, Nuclear Magnetic 
Resonance Spectroscopy and Mass Spectroscopy. 
 The purified compounds were screened for antitubercular activity by invitro Micro Plate 
Alamar Blue Assay. 
 The synthesized compounds SR1 and SR2 showed activity at 50 mcg/ml and 100 mcg/ml 
respectively. The MIC of known TB drugs Pyrazinamide: 3.125 mcg/ml, Ciprofloxacin: 
3.125 mcg/ml and Streptomycin 6.25 mcg/ml. 
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CONCLUSION 
 
 It is thus concluded that the synthesized compounds might effectively inhibit the chosen 
target, L, D Transpeptidase 2 which is crucial for the growth of Mycobacterium 
tuberculosis.  
 These molecules can be further modified structurally and more prospective potential 
molecules against the Mycobacterium tuberculosis can be developed. 
 
 
 
                
 
 
Bibliography 
 
Bibliography  
 
Department of pharmaceutical chemistry, Madras medical college. Page 63 
 
BIBLIOGRAPHY 
 
1. Core Curriculum on Tuberculosis: What the Clinician Should Know, sixth edition 2013. 
Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral 
Hepatitis, STD and TB Prevention, Division of Tuberculosis Elimination. 
 
2. Ashok Rattan, Awdhesh Kalia, and Nishat Ahmad, Multidrug-Resistant Mycobacterium 
tuberculosis: Molecular Perspectives, Emerging Infectious Diseases, Volume 4, No. 2, 
April–June 1998. 
 
3. Michael S. Glickman and William R. Jacobs, Microbial Pathogenesis of Mycobacterium 
tuberculosis: Dawn of a Discipline, Cell, Vol. 104, 477–485, February 23, 2001. 
 
4. http://museumofhealthcare.ca/explore/exhibits/breath/etiology.html 
 
5. Nancy A. Knechel Tuberculosis: Pathophysiology, Clinical Features and Diagnosis, Critical 
Care Nurse, April 2009, vol. 29, Page no. 2 34-43. 
 
6. http://www.who.int/topics/tuberculosis/en/. Retrieved on 25.11.2013 
 
7. Tuberculosis articles by University of Maryland Medical Center (UMMC), Sep 3, 2013 
TDD: 1.800.735.2258. 
 
8. Centers for Disease Control and Prevention, USA, August 1, 2012, 800-CDC-INFO (800-
232-4636) TTY: (888) 232-6348. 
 
9. JoAnne L. Flynn and John Chan, Tuberculosis: Latency and Reactivation Infect. 
Immun.2001, 69(7):4195. 
 
10. Christian Lienhardt,Mario Raviglione,Mel Spigelman,Richard Hafner,Ernesto 
Jaramillo,Michael Hoelscher,Alimuddin Zumla and Jan Gheuens, New Drugs for the 
Bibliography  
 
Department of pharmaceutical chemistry, Madras medical college. Page 64 
 
Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future, 
Journal of Infectious Diseases Advance Access published March 23, 2012. 
 
11. Mohammad Asif, Anita Singh, Lakshmayya, Review Article: Development of structurally 
diverse Antitubercular molecules with pyridazine ring, Year 2013, Volume 4, Issue 1, Page 
1-8. 
 
12. Xia Zhang, Jing Guo, Advances in the treatment of pulmonary tuberculosis, J Thorac Dis 
2012, Volume 4(6), Page no.617-623. 
 
13. Brennan PJ. Structure, function, and biogenesis of the cell wall of Mycobacterium 
tuberculosis, Tuberculosis, 2003, Volume 83, Page no.91-97. 
 
14. Sabri B. Erdemli,  Radhika Gupta,  William R. Bishai, Gyanu Lamichhane, L. Mario Amzel, 
Mario A. Bianchet.
 
Targeting the Cell Wall of Mycobacterium tuberculosis: Structure and 
Mechanism of L,D-Transpeptidase 2, Structure, Volume 20, Issue 12, 5 December 
2012,2103-2115. 
 
15. Dominic Both, Eva Maria Steiner, Daniela Stadler, Ylva Lindqvist, Robert Schnell, and 
Gunter Schneider, Acta Crystallogr D Biol Crystallogr. 2013 March 1; 69(Pt 3): 432–441 
 
16. Burgers Medicinal Chemistry, 6th Edition, Volume 1, 77-85. 
 
17. Nouri Neamati, Joseph J Barchi Jr, New paradigms in drug design and discovery,  Current 
topics in medicinal chemistry,2002, Volume 2(3), Page no.211-227. 
 
18. Dipali Singh et al. An Overview of Computational Approaches in Structure Based Drug 
Design. Nepal journal of Biotechnology.Dec.2011, Vol.2, 53–61  
 
19. A Baldi. Computational approaches for drug design and discovery: An overview, Systematic 
Reviews in Pharmacy, 2010, Vol. 1, No. 1, 99-105. 
Bibliography  
 
Department of pharmaceutical chemistry, Madras medical college. Page 65 
 
 
20. Md. Mofizur Rahman, Md. Rezaul Karim, Md. Qamrul Ahsan, Abul Bashar Ripon Khalipha, 
Mohammed Raihan Chowdhury  and Md Saifuzzaman, Use of computer in drug design and 
drug discovery: A  Review, International Journal of Pharmaceutical and Life Sciences 
ISSN 2305-0330  September 2012,Volume 1, Issue 2, Serial 5. 
 
21. Lin J, Sahakian DC, de Morais SM, Xu JJ, Polzer RJ, Winter SM, The role of absorption, 
distribution, metabolism, excretion and toxicity in drug discovery, Curr Top Med Chem. 
2003, 3(10):1125-54. 
 
22. Chetana B Patil et al, Chalcone: A Versatile Molecule, J. Pharm. Sci. & Res. Vol.1(3), 2009, 
11-22 
 
23. Nitin G. Ghodile, P. R. Rajput, V. W. Banewar and A. R. Raut, Activity of Some Chalcones 
And Flavones Having 2-Hydroxy Acetophenone Moiety,  Int J Pharm Bio Sci 2012 July; 
3(3): (P)389 – 395. 
 
24. Sweety, S. Kumar, K. Nepali, S. Sapra, O. P. Suri, K. L. Dhar, G. S. Sarma, and A. K. 
Saxena,  Synthesis and Biological Evaluation of Chalcones having Heterosubstituent(s), 
Indian J Pharm Sci. 2010 Nov-Dec; 72(6): 801–806. 
 
25. Pavan Kumar Padarthi and Elangovan Namasivayam, Synthesis and Biological Evaluation of 
Chalcones from 2-Acetyl-5- Methylfuran, International Journal of Pharmaceutical Science 
and Research, 2013, Issue 7, Volume 4, Page no.2629-2638. 
 
26. Vikas Tiwari, Jayant P. Singh, Parul Sharma, Laxmi lal Dangi, Shiv S. Dulawat, Microwave 
assisted improved synthesis of chalcones under microwave irradiation and their antibacterial 
activity, J.Chem.Bio.Phy.Sci. 2011, 1, (Vo.1) 22-27. 
 
 
Bibliography  
 
Department of pharmaceutical chemistry, Madras medical college. Page 66 
 
27. Bhagyesh Baviskar, Sureshbhi Patel, Bhushan Baviskar, SS Khadabadi and Mahendra 
Shiradkar,  Design and Synthesis of Some Novel Chalcones as Potent Antimicrobial Agent, 
Asian J. Research Chem.Volume1(2),Oct.-Dec.2008, Page 67-69. 
 
28. Nitin Kumar, Sushil Kumar, Himanshu Gupta, Sharma P.K, 3-Hydroxy-2- (Substituted 
Phenyl) -4h-Chromen-4-One Derivatives-Synthesis, Spectral Characterization and 
Pharmacological Screening, World Research Journal of Biochemistry, Volume 1, Issue 1, 
2012, page no.01-05. 
 
29. Seranthimata Samshuddin, Badiadka Narayana, Balladka Kunhanna Sarojini, Hemmige S. 
Yathirajan and  Ramappa Raghavendra, Synthesis, Characterization and Biological 
Evaluation of Functionalized Derivatives of Versatile Synthon 4,4 '-Difluoro chalcones, Der 
Pharma Chemica, 2012, 4(4):1445-1457. 
 
30. Text book of Elementary Organic Spectroscopy, Principles and chemical Applications by 
Y.R.Sharma, Page no: 123-125 
 
31. C.P. Sherman Hsu, Ph.D, Chapter 15: Infrared Spectroscopy, Handbook of Instrumental 
Techniques for Analytical Chemistry. 
 
32. Maryellen Nerz-Stormes, The Basics Nuclear Magnetic Resonance Spectroscopy, Organic 
Chemistry Study Aids Chemistry 211 and 212. 
 
33. Tai-huang Huang by An Introductory to NMR Spectroscopy. 
 
34.  Text book of Instrumental Analysis by Chatwal page no.2.292-2.296. 
 
35. Overview of Mass Spectrometry by Jared  Snider, Ph.D 
 
36. Jose de Jesus Alba-Romero et al, African Journal of Microbiology Research, Volume 5(26), 
pp.4659-4666, 16 November, 2011. 
Bibliography  
 
Department of pharmaceutical chemistry, Madras medical college. Page 67 
 
 
37. Scott G. Franzblau  et al, Rapid, Low-Technology MIC Determination with Clinical 
Mycobacterium tuberculosis Isolates by Using the Microplate Alamar Blue Assay, J. Clin. 
Microbiol. 1998, 36(2):362. 
 
38. Sephra N. Rampersad, Multiple Applications of Alamar Blue as an Indicator of Metabolic 
Function and Cellular Health in Cell Viability Bioassays, Sensors 2012, 12, 12347-12360. 
 
39. Glide: Schrodinger, Portland, or http://www.schrodinger.com 
 
40. Vengatachalam, C.M., Jiang.X., Oldfield., T and Waldman., M (2003) J. Mol. Graph. 
Model, 21, 289-307. 
 
41. Schnecke.,V. and Kuhn.,L.A., Perspect., Drug Discovery., Des.2008,volume 20,page 
no.171-190. 
 
42. Arshi Naqvi, Mohd. Shahnawaaz, Arikatla V. Rao and Daya S. Seth,Synthesis and anti-
microbial screening of 3-(3,4-Dimethoxyphenyl)-1-(2-hydroxy-5-methylphenyl)prop-2-en-
one and its heterocyclic analogs, ECSOC-13,30 nov.2009. 
 
43. Organic Chemistry,Reactions and Reagents by O.P.Agarwal,edition 42, page no.775-778. 
 
44. Nitin Kumar, Sushil Kumar, Himanshu Gupta, Sharma P.K., 3-Hydroxy-2- (Substituted 
Phenyl) -4h-Chromen-4-One Derivatives-Synthesis, Spectral Characterization and 
Pharmacological Screening, World Research Journal of Biochemistry, Volume 1, Issue 1, 
2012, pp.-01-05. 
 
 
45. Maria C. S. Lourenco, Marcus V. N. DeSouza, Alessandra C Pinheiro, Marcelle de L.                
Ferreira, Rasnisb B, Goncalves, Thais Cristina M Nogneira, Monica A Peralta, Evaluation of 
anti-Tubercular activity of nicotinic and isoniazid analogue, ARKIVOC 2007 (xv), 181-191. 
Bibliography  
 
Department of pharmaceutical chemistry, Madras medical college. Page 68 
 
 
46. Louise Domeneghini Chiaradia et al, Synthetic Chalcones as Efficient Inhibitors of 
Mycobacterium tuberculosis Protein Tyrosine Phosphatase PtpA, Bioorganic & Medicinal 
Chemistry Letters 18 (2008) 6227–6230  
 
47. M.Shahar Yar, A.Ahmad Siddiqui and M.Ashraf Ali, Synthesis and antimycobacterial 
activity of novel heterocycles, J. Serb. Chem. Soc.2007, 72 (1) 5–11.  
 
48. Sivakumar.P.M, Kumar.V, Seenivasan.S.P, Mohanapriya.J, Doble.M, Experimental and 
Theoretical approaches to enhance  Anti tubercular Activity of Chalcones, WSEAS Transac 
Biol Biomed; 2010; 7; 51-61. 
 
49. Jahirul Islam Talukdar, MonicaKachroo, Synthesis, Characterization, Antibacterial and 
Antitubercular Activity of Some Substituted N-[4-(3-Phenyl-Acryloyl)-Phenyl]-Benzamide, 
World Journal of Pharmaceutical research 2013, Volume 3, Issue 1, 900-909. 
 
50. Dr. Mrunmayee Toraskar, Suvarna Patil and Dr. Vilasrao Kada, Synthesis Of Thiophene-2-
Carboxylic Acid N'-(3-Aryl/Substituted Aryl/Heteroaryl-Acryloyl)-Hydrazide Derivatives As 
Anti-Fungal, Anti-Mycobacterial And Anti-Oxidnant Agents, International Journal of 
Universal Pharmacy and Bio Sciences 2(4): July-August 2013. 
 
51. M.M.H. Bhuiyan, M.I. Hossain, M.M. Mahmud and Mohammad Al-Amin, Microwave-
assisted Efficient Synthesis of Chalcones as Probes for Antimicrobial Activities, Chemistry 
Journal (2011), Vol. 01, Issue 01, pp. 21-28 
 
52. Hatish Prashar, Anshul Chawla, Anil Kumar Sharma and Rajeev Kharb, Chalcone as a 
Versatile Moiety for Diverse Pharmacological Activities, IJPSR, 2012; Vol. 3(7): 1913-1927.   
 
53. Nidhi Singh, Shamim Ahmad, M. Shamsher Alam, Biological Potentials of Chalcones: A 
Review, International Journal of Pharmaceutical & Biological Archives 2012; 3(6):1298-
130. 
Bibliography  
 
Department of pharmaceutical chemistry, Madras medical college. Page 69 
 
 
54. Kouskoura Maria, Hadjipavlou-Litina Dimitra and Giakoumakou Maria, Synthesis and Anti-
Inflammatory Activity of Chalcones and Related Mannich Bases, Medicinal Chemistry, 
2008, 4, 586-596. 
 
55. Suvitha Syam, Siddig Ibrahim Abdelwahab, Mohammed Ali Al-Mamary and Syam Mohan, 
Synthesis of Chalcones with Anticancer Activities, Molecules 2012, 17, 6179-6195. 
 
56. Kouskoura Maria, Hadjipavlou-Litina Dimitra and Giakoumakou Maria, Synthesis and Anti-
Inflammatory Activity of Chalcones and Related Mannich Bases, Medicinal Chemistry, 
2008, 4, 586-596. 
 
57. Sabri B. Erdemli, Radhika Gupta, William R. Bishai, Gyanu Lamichhane, L. MarioAmzel 
and Mario A. Bianchet, Targeting the cell wall of Mycobacterium tuberculosis: Structure and 
Mechanism of L,D-transpeptidase 2, Structure. 2012 December 5; 20(12): 2103–2115. 
 
58. Soumya De, Lawrence P. McIntosh, Putting a Stop to L,D-Transpeptidases, Structure, 
volume 20, May 9, 2012. 
 
59. Dominic Both, Eva Maria Steiner, Daniela Stadler, Ylva Lindqvist, Robert Schnell, and 
Gunter Schneider, Acta Crystallogr D Biol Crystallogr, 2013, March 1, Volume 69, Page 
no.432–441. 
 
60. Graham L. Patrick., An Introduction to Medicinal Chemistry, Fourth edition, Oxford 
publication, 519-575. 
 
61. http://en.wikipedia.org/wiki/Lipinski%27s_rule_of_five. Retrieved on 02.01.2014 
 
 
62. http://www.molinspiration.com/cgi-bin/properties. Retrieved on 07.03.2014 
 
63. http://www.organic-chemistry.org/prog/peo/ retrieved on 22.12.2013 
Bibliography  
 
Department of pharmaceutical chemistry, Madras medical college. Page 70 
 
 
64. C.N.Nalini, S. Raga Deepthi, N.Ramalakshmi and G.Uma, Toxicity Risk Assesment of 
Isatins, RASAYAN J.Chem. Vol.4, No.4 (2011), 829-837. 
 
